Latest Insider Transactions at Supernus Pharmaceuticals, Inc. (SUPN)
This section provides a real-time view of insider transactions for Supernus Pharmaceuticals, Inc. (SUPN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SUPERNUS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SUPERNUS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 07
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Open market or private sale
|
Direct |
15,000
-64.66%
|
$540,000
$36.98 P/Share
|
|
Nov 07
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+39.27%
|
$135,000
$9.13 P/Share
|
|
Nov 07
2024
|
Jack A. Khattar President, CEO |
SELL
Open market or private sale
|
Direct |
125,000
-11.89%
|
$4,500,000
$36.68 P/Share
|
|
Nov 07
2024
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+10.63%
|
$1,125,000
$9.13 P/Share
|
|
Nov 07
2024
|
Georges Gemayel Director |
SELL
Open market or private sale
|
Direct |
14,213
-51.63%
|
$511,668
$36.62 P/Share
|
|
Nov 07
2024
|
Georges Gemayel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,213
+34.05%
|
$156,343
$11.46 P/Share
|
|
Sep 13
2024
|
Georges Gemayel Director |
SELL
Open market or private sale
|
Direct |
13,886
-32.74%
|
$430,466
$31.33 P/Share
|
|
Sep 13
2024
|
Georges Gemayel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+30.02%
|
$110,000
$11.46 P/Share
|
|
Sep 03
2024
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,045
-1.07%
|
$341,530
$34.9 P/Share
|
|
Sep 03
2024
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+2.19%
|
-
|
|
Aug 20
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-5.58%
|
$16,588
$29.57 P/Share
|
|
Aug 20
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+10.87%
|
-
|
|
Mar 21
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
14,491
-62.84%
|
$507,185
$35.31 P/Share
|
|
Mar 21
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,491
+38.59%
|
$362,275
$25.3 P/Share
|
|
Mar 20
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
400
-4.46%
|
$14,000
$35.31 P/Share
|
|
Mar 20
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+4.27%
|
$10,000
$25.3 P/Share
|
|
Mar 19
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
12,364
-59.06%
|
$432,740
$35.31 P/Share
|
|
Mar 19
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,364
+37.13%
|
$309,100
$25.3 P/Share
|
|
Mar 13
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
62,366
-78.1%
|
$2,058,078
$33.79 P/Share
|
|
Mar 13
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
62,366
+43.84%
|
$1,122,588
$18.49 P/Share
|
|
Mar 12
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
3,884
-31.19%
|
$124,288
$32.99 P/Share
|
|
Mar 12
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,884
+23.77%
|
$46,608
$12.98 P/Share
|
|
Feb 28
2024
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,788
-1.8%
|
$453,276
$27.94 P/Share
|
|
Feb 28
2024
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+3.62%
|
-
|
|
Feb 28
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
460
-5.58%
|
$12,420
$27.94 P/Share
|
|
Feb 28
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
990
+10.73%
|
-
|
|
Feb 26
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
5,000
-36.85%
|
$150,000
$30.21 P/Share
|
|
Feb 26
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+26.93%
|
$45,000
$9.13 P/Share
|
|
Feb 23
2024
|
Frederick M. Hudson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,886
+9.48%
|
-
|
|
Feb 23
2024
|
Georges Gemayel Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,886
+18.43%
|
-
|
|
Feb 23
2024
|
Carrolee Barlow Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,886
+18.43%
|
-
|
|
Feb 23
2024
|
Charles W Newhall Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,886
+3.11%
|
-
|
|
Feb 23
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
485
-0.55%
|
$14,065
$29.06 P/Share
|
|
Feb 23
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+1.41%
|
-
|
|
Feb 23
2024
|
Jonathan Rubin SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
567
-10.89%
|
$16,443
$29.06 P/Share
|
|
Feb 23
2024
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+19.36%
|
-
|
|
Feb 23
2024
|
Timothy C Dec Senior Vice-President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,314
-15.45%
|
$38,106
$29.06 P/Share
|
|
Feb 23
2024
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+22.72%
|
-
|
|
Feb 23
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
638
-6.93%
|
$18,502
$29.06 P/Share
|
|
Feb 23
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+11.95%
|
-
|
|
Feb 23
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
937
-11.45%
|
$27,173
$29.06 P/Share
|
|
Feb 23
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Grant, award, or other acquisition
|
Direct |
1,875
+18.64%
|
-
|
|
Feb 23
2024
|
John M Siebert Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,886
+4.23%
|
-
|
|
Feb 22
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
246
-0.28%
|
$6,642
$27.94 P/Share
|
|
Feb 22
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
750
+0.86%
|
-
|
|
Feb 22
2024
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
500
+7.69%
|
-
|
|
Feb 22
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
335
-5.04%
|
$9,045
$27.94 P/Share
|
|
Feb 22
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Grant, award, or other acquisition
|
Direct |
750
+10.14%
|
-
|
|
Feb 22
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
372
-4.47%
|
$10,044
$27.94 P/Share
|
|
Feb 22
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
750
+8.26%
|
-
|